findmyKOL

Farnoosh Farrokhi

Basic profile

Sutter Health

ORCIDNone on fileNPI
RegionCastro Valley, CA · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Farnoosh Farrokhi is an Endocrinology/Metabolic physician affiliated with Sutter Health. OpenAlex indexes 31 publications with 988 citations (h-index 14).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
31publications

Distinct works indexed by OpenAlex.

988citations

Total citations across indexed works.

14h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

20101 Lake Chabot Rd
3rd Floor
Castro Valley, CA 945465305

Telephone

510-247-6405

Registry record last updated 28 Apr 2016.

View the NPPES registry record

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    50.4%
    RANK Ligand Inhibitor50.4%
    Denosumab100%
    Part B, office-administered21 patients
  • Metabolism & gastrointestinal

    27.8%
    GLP-1 receptor agonist9.7%
    Ozempic44%Trulicity24%Rybelsus16%Mounjaro16%
    Part D58 patients
    SGLT2 inhibitor5.4%
    Jardiance95%Farxiga5%
    Part D<11 patients

    + 6 more classes in this area

  • Cardiovascular

    13.8%
    Statin4.9%
    Atorvastatin Calcium77%Rosuvastatin Calcium15%Simvastatin9%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)1.9%
    Losartan Potassium87%Valsartan13%
    Part D<11 patients

    + 10 more classes in this area

Where care is delivered (Part B)6.5% facility · 93.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”